This FAQ delves into the promising trends and developments in non-small cell lung cancer (NSCLC). DOWNLOAD THE FULL REPORT HERE

What is the global distribution of NSCLC trials, and which regions are leading in research efforts?  

The clinical trial landscape reveals a diverse engagement, with Europe leading with over 50% of the trials and the Asia-Pacific (APAC) region, especially Mainland China and South Korea, contributing approximately 40% of NSCLC trials. This collective effort underscores a global commitment to advancing research and development in NSCLC, reflecting the widespread prevalence of this type of lung cancer worldwide.

What are the key characteristics and prevalence of NSCLC globally?

NSCLC, accounting for 80-85% of all lung cancer cases, primarily originates from larger cells in the airway lining. In 2020, Asia reported over 1,000,000 cases of NSCLC, particularly from countries like China, India, and Japan, while Europe had around 400,000 cases. Genetic mutations in NSCLC show variations between Asian and non-Asian patients, with a higher frequency of EGFR mutations in Asian populations and a higher prevalence of KRAS mutations in European populations.

What treatment options are available for NSCLC patients, and how are these treatments determined?

Treatment options for NSCLC depend on various factors, such as tumor size, location, and histology. These include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The National Comprehensive Cancer Network (NCCN) guidelines provide specific treatment recommendations for different stages of NSCLC, tailoring the use of various drugs and therapies based on the tumor's unique characteristics.

What recent trends have been observed in NSCLC clinical trials globally?

Since 2018, the global biopharma industry has been actively involved in over 3,000 NSCLC clinical trials. Notable contributors to these trials include the United States, Mainland China, Spain, and South Korea.  

The collective efforts of researchers and institutions globally have significantly advanced our understanding and treatment of NSCLC. As we continue to witness the evolution of the clinical trial landscape, it remains crucial to stay informed about the latest research developments and contributions made by experts in the field, ultimately leading to improved patient care and outcomes in the fight against NSCLC.

What does the future hold for NSCLC research?

As the clinical trial landscape continues to evolve, it is evident that the Asia-Pacific region has positioned itself as a dynamic hub for NSCLC research, showcasing robust growth rates and streamlined recruitment processes. Simultaneously, the concerted efforts of regional key opinion leaders, have further propelled the advancements in understanding and treating NSCLC. With promising trends in venture capital funding and a growing emphasis on innovation, the global commitment to combat NSCLC remains steadfast, emphasizing the urgency and importance of collaborative research and development efforts to combat this prevalent form of cancer worldwide.